Pasithea Therapeutics Corp.

KTTA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001841330

Other share classesKTTAW

Price chart

Open-market purchases and sales by KTTA insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Jun 22, 2026Jun 17, 2026Coastlands Capital LP10% OwnerPPurchaseCommon Stock+100K$0.53+$53K3.84M+2.7%SEC
Dec 1, 2025Nov 28, 2025STEINMAN LAWRENCEDirectorPPurchaseCommon Stock+133.33K$0.75+$100K199.69K+200.9%SEC
Dec 1, 2025Nov 28, 2025Marques TiagoChief Executive OfficerPPurchaseCommon Stock+33.33K$0.75+$25K73.33K+83.3%SEC
Dec 1, 2025Nov 28, 2025Dumesnil SimonDirectorPPurchaseCommon Stock+33.33K$0.75+$25K35.83K+1,333.3%SEC
May 14, 2025May 12, 2025Marques TiagoChief Executive OfficerSSaleCommon Stock−960$0.83−$796.840K−2.3%SEC

The largest institutional positions in KTTA at the end of Q2 2026.

Institutions holding KTTA in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Cable Car Capital LLC3,000,000$1.55M0.03%+1,793,621+148.7%Added
Stonepine Capital Management, LLC2,201,468$1.13M0.86%+1,370,167+164.8%Added
Jupiter Topco LLC2,100,000$1.09M0.00%+2,100,000New
ADAGE CAPITAL PARTNERS GP, L.L.C.2,100,000$1.08M0.00%00.0%Unchanged
Opaleye Management Inc.2,050,000$1.06M0.10%+2,050,000New